Anthony Rosenzweig, M.D.
Harvard Medical School
The Rosenzweig lab focuses on heart failure and understanding the clinical implications of fundamental biological processes regulating cell growth, death and regeneration in the heart.
Heart failure is an enormous and growing cause of death and disability throughout the world. In addition, the heart provides a model system for studying fundamental cellular processes from cell growth and programmed death, to cell-lineage determination and regeneration.
The Rosenzweig lab is interested in understanding how exercise protects the heart against heart failure. A variety of high throughput profiling techniques are being used to identify pathways differentially regulated in heart growth associated with exercise in comparison to the heart growth that precedes heart failure. These screens have identified interrelated transcriptional (Cell, 2010) and microRNA pathways (Cell Metabolism, 2015), which appear to mediate many of the phenotypic effects of exercise in vivo. Collaborative studies with Rich Lee’s laboratory are investigating the role of exercise in enhancing the endogenous regenerative capacity of the adult mammalian heart.
Anthony Rosenzweig is the Chief of Cardiology and Co-Director of the Corrigan-Minehan Heart Center at the Massachusetts General Hospital (MGH), and the Paul Dudley White Professor of Medicine at Harvard Medical School. Previous leadership roles include having served as the Director of the Program in Cardiovascular Gene Therapy at MGH (1999-2006), an Associate Editor of the New England Journal of Medicine (2003-2013), and a Trustee of the Harvard Clinical Research Institute (2008-2015), an academic CRO, as well as the Director of Cardiovascular Research and Associate Chief of Cardiology at the Beth Israel Deaconess Medical Center (2006-2015).
Rosenzweig has had a consistent interest in the translational implications of basic research, and is a co-inventor on novel approaches to cardiovascular diagnosis and therapy currently licensed or in clinical trials. He is also a committed mentor who has personally supervised over 50 research fellows in his laboratory. Most who have left the laboratory have gone on to full-time academic faculty positions with substantial research commitments and of these, nine hold major leadership positions.
Rosenzweig serves as the Program Director for the MGH NIH cardiovascular T32 training grant and previously served on the Scientific Board of the Sarnoff Foundation, an organization devoted to mentoring young investigators. Previous awards and honors include the Roman W. DeSanctis Clinical Scholar Award, an Established Investigator Award of the American Heart Association, and election into the American Society for Clinical Investigation (ASCI) and the American Association of Physicians (AAP).
- C/EBPβ controls exercise induced cardiac growth and protects against pathological cardiac remodeling. Boström P, Mann N, Wu J, Quintero PA, Plovie E, Gupta R, Xiao C, MacRae CA, Rosenzweig A* and Spiegelman BM* (*contributed equally, co-corresponding). Cell 2010;143:1072-1083.
- Ashida N, Senbanerjee S, Kodama S, Foo SY, Coggins M, Spencer JA, Zamiri P, Shen D, Li L, Sciuto T, Dvorak A, Gerszten RE, Lin CP, Karin M, Rosenzweig A. IKKb regulates essential functions of the vascular endothelium through kinase-dependent and -independent pathways. Nature Commun. 2011;2:318(1-9).
- Platt, C.*, Houstis, N.*, Rosenzweig, A. Using exercise to measure and modify cardiac function. Cell Metabolism 2015; 21(2): 227-36. PMCID: 4317572. *co-first authors; contributed equally.
- Liu X*, Xiao J*, Zhu H, Wei X, Platt C, Damilano F, Xiao C, Bezzerides V, Boström P, Che L, Zhang C, Spiegelman BM, and Rosenzweig A. miR-222 is Necessary for Exercise-induced Cardiac Growth and Protects Against Pathological Cardiac Remodeling. Cell Metabolism 2015; 21(4): 584-595. PMCID: 4393846. *co-first authors; contributed equall